Melanoma as a model tumour for immuno-oncology

Annals of Oncology

Volumn 23, Issue SUPPL.8, 2012, Pages

  Maio, M ^a  

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

Immuno oncology; Immunotherapy; Melanoma; Model; Tumour associated antigens; Vitiligo

Indexed keywords

ALPHA2B INTERFERON; CISPLATIN; DACARBAZINE; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; IPILIMUMAB; MELANOMA ANTIGEN; TICILIMUMAB; TUMOR ANTIGEN; VEMURAFENIB; VINBLASTINE;

ADOPTIVE TRANSFER; ANTIGEN EXPRESSION; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CONFERENCE PAPER; DEPIGMENTATION; DRUG MEGADOSE; HUMAN; IMMUNE SYSTEM; IMMUNO ONCOLOGY; MELANOMA CELL; METASTATIC MELANOMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN ANALYSIS; TREATMENT RESPONSE; TUMOR IMMUNOLOGY; TUMOR REGRESSION; VITILIGO;

ADOPTIVE TRANSFER; ANTIGENS, NEOPLASM; CYTOKINES; HUMANS; IMMUNOTHERAPY; MELANOMA; NEOPLASM REGRESSION, SPONTANEOUS; SKIN NEOPLASMS; TREATMENT OUTCOME; VITILIGO;

EID: 84865559786     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds257     Document Type: Conference Paper

References (36)

1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765-781.
2. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
3. Korn EL, Liu PY, Lee SJ et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008; 26: 527-534.
4. Garbe C, Peris K, Hauschild A et al. Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer 2010; 46: 270-283.
5. ® (aldesleukin) prescribing information. http://www.proleukin com/health-care-professional/tools/pijsp (October 2011, date last accessed).
6. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.
7. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
8. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-2526.
9. Houghton AN, Gold JS, Blachere NE. Immunity against cancer: lessons learned from melanoma. Curr Opin Immunol 2001; 13: 134-140.
10. Faries MB, Morton DL. Melanoma: is immunotherapy of benefit? Adv Surg 2003; 37: 139-169.
11. Boon T, van der BP. Human tumor antigens recognized by T lymphocytes. J Exp Med 1996; 183: 725-729.
12. Castelli C, Rivoltini L, Andreola G et al. T-cell recognition of melanomaassociated antigens. J Cell Physiol 2000; 182: 323-331.
13. Epping MT, Bernards R. A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancer. Cancer Res 2006; 66: 10639-10642.
14. Fratta E, Coral S, Covre A et al. The biology of cancer testis antigens: putative function, regulation and therapeutic potential. Mol Oncol 2011; 5: 164-182.
15. Kawakami Y, Rosenberg SA. Human tumor antigens recognized by T-cells. Immunol Res 1997; 16: 313-339.
16. Lupetti R, Pisarra P, Verrecchia A et al. Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage. J Exp Med 1998; 188: 1005-1016.
17. Kalialis LV, Drzewiecki KT, Klyver H. Spontaneous regression of metastases from melanoma: review of the literature. Melanoma Res 2009; 19: 275-282.
18. Printz C. Spontaneous regression of melanoma may offer insight into cancer immunology. J Natl Cancer Inst 2001; 93: 1047-1048.
19. Wenzel J, Bekisch B, Uerlich M et al. Type I interferon-associated recruitment of cytotoxic lymphocytes: a common mechanism in regressive melanocytic lesions. Am J Clin Pathol 2005; 124: 37-48.
20. Reiman JM, Kmieciak M, Manjili MH et al. Tumor immunoediting and immunosculpting pathways to cancer progression. Semin Cancer Biol 2007; 17: 275-287.
21. Speeckaert R, van GN, Vermaelen KV et al. Immune reactions in benign and malignant melanocytic lesions: lessons for immunotherapy. Pigment Cell Melanoma Res 2011; 24: 334-344.
22. van den Wijngaard R, Wankowicz-Kalinska A, Pals S et al. Autoimmune melanocyte destruction in vitiligo. Lab Invest 2001; 81: 1061-1067.
23. Le Gal FA, Avril MF, Bosq J et al. Direct evidence to support the role of antigenspecific CD8(+) T cells in melanoma-associated vitiligo. J Invest Dermatol 2001; 117: 1464-1470.
24. Phan GQ, Attia P, Steinberg SM et al. Factors associated with response to highdose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 2001; 19: 3477-3482.
25. Boasberg PD, Hoon DS, Piro LD et al. Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma. J Invest Dermatol 2006; 126: 2658-2663.
26. Rubin K. Management of metastatic melanoma: nursing challenges today and tomorrow. Clin J Oncol Nurs 2009; 13: 81-89.
27. Atkins MB, Lotze MT, Dutcher JP et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17: 2105-2116.
28. Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 2009; 21: 233-240.
29. Wrzesinski C, Paulos CM, Kaiser A et al. Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J Immunother 2010; 33: 1-7.
30. Dudley ME, Gross CA, Langhan MM et al. CD8+ enriched " young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res 2010; 16: 6122-6131.
31. Blank C, Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother 2007; 56: 739-745.
32. Amos SM, Duong CP, Westwood JA et al. Autoimmunity associated with immunotherapy of cancer. Blood 2011; 118: 499-509.
33. Lens M, Ferrucci PF, Testori A. Anti-CTLA4 monoclonal antibody ipilimumab in the treatment of metastatic melanoma: recent findings. Recent Pat Anticancer Drug Discov 2008; 3: 105-113.
34. Balch CM, Buzaid AC, Soong SJ et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635-3648.
35. Sigalotti L, Fratta E, Bidoli E et al. Methylation levels of the " long interspersed nucleotide element-1" repetitive sequences predict survival of melanoma patients. J Transl Med 2011; 9: 78.
36. Cordaux R, Batzer MA. The impact of retrotransposons on human genome evolution. Nat Rev Genet 2009; 10: 691-703.